Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (251-260 of 336) with videos related to

Pageof 34
Sort By:
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2023
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE studyMelissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapyAndrea De Giglio, Alessandro Leonetti, Francesca Comito, et al.
The Oncologist|October 5, 2023
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort StudyFederica Pecci, Luca Cantini, Valeria Cognigni, et al.
Scientific Reports|March 12, 2026
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumorsGiulia Bruschi, Francesco Paoloni, Federica Pecci, et al.
Future Oncology (London, England)|April 29, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Future Oncology (London, England)|June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
International Journal of Cancer|November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Pageof 34

Showing results (251-260 of 336) with videos related to

Sort By:
Pageof 34
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2023
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE studyMelissa Bersanelli, Alessio Cortellini, Alessandro Leonetti, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapyAndrea De Giglio, Alessandro Leonetti, Francesca Comito, et al.
The Oncologist|October 5, 2023
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort StudyFederica Pecci, Luca Cantini, Valeria Cognigni, et al.
Scientific Reports|March 12, 2026
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumorsGiulia Bruschi, Francesco Paoloni, Federica Pecci, et al.
Future Oncology (London, England)|April 29, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Future Oncology (London, England)|June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
International Journal of Cancer|November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Pageof 34